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Confers Constitutive Signaling, Favors Tumorigenic
Properties, and Is Sensitive to Imatinib
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TO THE EDITOR
Melanomas belong to a heterogeneous
group of neoplasms essentially affecting
skin, mucous membrane, or uvea. Skin
melanomas have been classified in four
clinical subtypes, e.g., superficial spre-
ading, nodular, lentigo maligna, and
acral melanomas, each of them being
endowed with specific genetic altera-
tions thought to be causative of the
disease development (Curtin et al.,
2005; Whiteman et al., 2011). Acral,
lentigo maligna, and mucosal mela-
nomas share the characteristic of freque-
ntly having a constitutive activation of
the KIT pathway caused by amplifi-
cation and/or by gain-of function
mutation of KIT (Curtin et al., 2006;
Beadling et al., 2008; Satzger et al.,
2008). About 15% of these melanoma
subtypes have a KIT mutation. Most
mutations occur in exons 11, 13, and
17, the most frequent being the
missense mutations L576P and K642E.
These mutations generally lead to the
constitutive activation of associated
signaling pathways, including the PI3
kinase and ERK pathways (Alexeev and
Yoon, 2006; Ashida et al., 2009; Monsel
et al., 2010; Liang et al., 2011).
Several groups reported major clinical
responses to imatinib in patients with
metastatic melanoma expressing
mutated KIT (Hodi et al., 2008; Lutzky
et al., 2008; Handolias et al., 2010;
Satzger et al., 2010; Carvajal et al.,
2011), pointing to KIT inhibitors as an
attractive treatment for melanomas with
constitutive KIT pathway activation.
A 70-year-old patient originating from
the Middle East presented in our depart-
ment for subcutaneous metastases from
an acral lentiginous melanoma of the first
left toe with a Breslow thickness of
4.8mm treated surgically one year before.
A routine mutation analysis showed no
BRAF mutation at position V600, no
NRAS mutation at positions G12 and
Q61, and no KIT mutation in exons 11,
13, and 17. Complete KIT sequencing of
the genomic DNA extracted from the
primary lesion and from a subcutaneous
metastasis revealed a c.1514A4T point
mutation (Figure 1a). This mutation,
which has never been described before
in melanoma, results in the substitution of
asparagine 505 by an isoleucine (N505I),
within the exon 9 that encodes the fifth
external immunoglobulin superfamily
domain (Supplementary Figure S1
online). A similar substitution N505H
has been found recently in a case of
acral melanoma (Schilling et al., 2013)
and the coexistence of N505I and D820E
mutations has been described in a tumor
from a patient with gonadoblastoma
and dysgerminoma (Hersmus et al.,
2012). (Note that in our case no D820E
mutation was found in the exon 17).
The sequencing chromatograms
suggested that the patient carried a
homozygous N505I mutation, an un-
usual scenario since KIT is an oncogene.Accepted article preview online 6 December 2013; published online 9 January 2014
Abbreviations: SCF, stem cell factor also known as KIT-ligand; WT, wild type
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In addition, the mutation was not
detected in the DNA from patient blood
or from a dermal nevus, ruling out the
possibility of a germinal mutation and a
subsequent loss of heterozygosity on the
second allele (Figure 1a). Therefore, an
analysis of the KIT gene copy number
was undertaken using quantitative PCR.
Analysis of DNA from two unrelated
melanomas, the patient’s blood, and
nevus showed, as expected, the exis-
tence of two copies of KIT. However,
the primary lesion had 10 copies of KIT,
whereas 30 copies were detected in the
metastasis (Figure 1b). As the sequen-
cing of the lesions detected a very small
peak corresponding to the wild-type
(WT) allele, we concluded that, subse-
quent to the c.1514A4T mutation, the
mutated allele underwent a genomic
amplification. Mutant allele specific
imbalance has been frequently reported
in mutant EGFR and KRAS (Modrek et al.,
2009) and a specific amplification of the
mutated KIT allele has been previously
reported in melanoma with the KIT
K642E mutation (Curtin et al., 2006).
Immunohistochemistry analysis of the
primary tumor using anti-KIT antibody
(Figure 1c) showed that the tumor masses
seen in routine histology (upper left
panel) were strongly labeled with anti-
KIT antibody (upper right panel). Virtually
all the tumoral cells expressed high level
of KIT. In the metastasis, the vast majority
of tumor cells also showed strong expres-
sion of KIT (Figure 1c, lower left panel).
These observations are in perfect agree-
ment with the genomic amplification
described above. No labeling was
observed with a control isotype antibody
(Figure 1c, lower right panel).
Next we sought to evaluate the effects
of the N505I mutation on the biological
behavior of MelanA cells. To do so, the
N505I mutation was introduced by site-
directed mutagenesis (Quickchange,
Agilent, France) into WT c-Kit cDNA,
cloned in the pMCEF vector (Monsel
et al., 2010). Mutation was confirmed
by sequence analysis. Then, we
generated stable MelanA cell lines
either expressing the WT or the N505I
mutant form of KIT. As control, we used
cells transfected with empty plasmid
(Ctl). Expression of KIT-N505I incre-
ased cell growth compared to control
or KIT-WT-expressing cells when
cultured in the absence of stem cell
factor also known as KIT-ligand (SCF)
(Supplementary Figure S2 online). Mel-
anA cells expressing the KIT-N505I also
had an increased motility compared to
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Figure 1. New N505I KIT mutation in melanoma is associated with genomic amplification and overexpression. (a) Sanger sequencing chromatograms
showing the c.1514A4T (N505I) mutation in primary melanoma of the first left toe and in skin metastasis. Blood and nevus do not harbor this mutation.
(b) Quantification of KIT copy number, using a TaqMan copy number assay (Applied Biosystems). (c) Upper panels, hematoxylin and eosin staining and
immunostaining with KIT antibody (#A4502, 1/50, Dako France) of the primary lesion. Lower panels, immunostaining with (KIT) and without (Ctl) KIT antibody
of the skin metastasis. KIT expression was revealed by peroxidase labeled secondary antibody. Scale bar¼ 200mm.
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control or KIT-WT-expressing cells as
shown by the Boyden chambers assays
(Figure 2a). Further, when evaluating the
capacity of the cells to grow in soft agar, a
characteristic of transformed cells, we
observed that only the KIT-N505I expres-
sing cells were able to form colonies
when exposed to SCF, while control or
KIT-WT cells did not (Figure 2b). Other
oncogenic KIT mutants (K642E and
L576P) were reported to require HIF1a
overexpression to transform MelanA cells
(Monsel et al., 2010). Therefore, it seems
that the KIT-N505I mutant does not need
to cooperate with HIF1a to transform
melanocytes. However, we cannot rule
out that the conditions we used for soft-
agar experiments, mimicked somehow
the hypoxic conditions, favoring thereby
colony formation. Taken together, these
results indicate that the KIT-N505I mutant
confers to melanocytes some of the
features of melanoma cells.
Then, we studied the KIT-N505I signal-
ing capacity. Control, KIT-WT, or KIT-
N505I cells were exposed or not to SCF
and analyzed for KIT downstream signaling
pathways (Figure 2c). Western blot with
KIT antibody showed that KIT-WT and KIT-
N505I cells express similar level of KIT,
much higher than the control cells. Phos-
pho-KIT antibody showed that the over-
expression of KIT is sufficient to increase
KIT autophosphorylation. The mutant
showed consistently an increased basal
autophophorylation. KIT-WT or -N505I
allowed SCF to activate efficiently ERK
and AKT pathways, as shown by western
blot with phosphospecific antibodies. We
frequently observed a stronger phosphor-
ylation of ERK and AKT with the KIT-
N505I cells, in basal conditions, which is
in agreement with the increased autopho-
sphorylation observed above. These results
indicate that the KIT-N505I mutant has an
increased signaling capacity. It seems that
the N505I mutation leads to a weak, but
reproducible constitutive basal activation.
Nevertheless, we cannot rule out that the
mutation rather sensitizes KIT to low levels
of SCF, potentially produced by the cells.
However, the analysis of an SCF dose
response effect on KIT autophosphorylation
(Supplementary Figure S3 online), did not
demonstrate an increased sensitivity of the
KIT-N505I mutant to its ligand. Again we
cannot rule out the possibility that such an
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Figure 2. The KIT-N505I mutant has exacerbated transforming ability and signaling properties. (a) Migration ability of MelanA (Ctl), MelanA expressing wild type
(WT), or N505I mutant (N505I) KIT was evaluated using Boyden chambers. Cells were seeded in serum-depleted medium in the upper chambers, and 7% fetal calf
serum was used as attractant in the lower chambers. Left panel shows representative pictures of the bottom face of the chambers after coloration with 0.4% crystal
violet. Right panel, quantification of three independent experiments, results are means±SD. (b) Anchorage independent growth of MelanA cells expressing WT or
N505I KIT was evaluated in soft agar, in presence or in absence of stem cell factor (SCF) 100 ng ml1. Pictures show the result of a representative experiment
(n¼ 2). (c) MelanA Ctl, or MelanA WT, or MelanA N505I cells were exposed to SCF 100 ng ml1 for 10 min. Then solubilized proteins were analyzed by western
blot with antibodies to KIT (#sc-168, 1/1,000, Santa Cruz Biotechnology), phospho-Tyr719-KIT (p-KIT, #3391, 1/1,000, Cell Signaling Technology), phospho-
Thr202/Tyr204-ERK (p-ERK, #9101, 1/1,000 Cell Signaling Technology), or phospho-Ser473-AKT (p-AKT, #9271, 1/1,000, Cell Signaling Technology), and ERK2
(#sc-154, 1/1,000, Santa Cruz Biotechnology) was used as loading control. (d) The same experiment as in c was performed in the presence of imatinib (Im.) or
sorafenib (Sora.) 5mM for 1 h before exposition to SCF for 10 min.
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effect can be masked by the autocrine
production of SCF.
Finally, we evaluated the effects of two
KIT inhibitors, imatinib (Carvajal et al.,
2011) and sorafenib (Heinrich et al., 2012)
on the signaling pathways activated in
KIT-N505I expressing cells. Sorafenib,
and imatinib to a lesser extent, inhibited
SCF-induced KIT autophosphorylation as
well as ERK and AKT phosphorylations in
these cells (Figure 2d). Therefore, the KIT-
N505I mutation did not abolish the sensi-
tivity of KIT to these inhibitors.
To conclude, we described a new
KIT-N505I mutation in an acral lentiginous
melanoma that confers the receptor
an increased basal activity, associated
with exacerbated signaling properties.
The respective roles of mutation and over-
expression of KIT in the acquisition of
tumorigenic properties by these melanoma
cells remain to be elucidated. Never-
theless, patients with melanoma bearing
the KIT-N505I mutation might be eligible
for treatment with imatinib or sorafenib.
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Prognostic Impact of p62 Expression in Cutaneous
Malignant Melanoma
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TO THE EDITOR
Accumulating evidence suggests auto-
phagy, the principle catabolic process
for lysosomal degradation of surplus
macromolecules (Roy and Debnath,
2010), is fundamental to tumorigenesis.
Impaired autophagy results in accumu-
lation of cellular breakdown products,
increased oxidative stress and neoplastic
transformation (Mathew et al., 2009);
whilst efficient autophagy facilitates
metastatic tumor survival through
sustained metabolic activity (Roy and
Debnath, 2010). Consequently, theAccepted article preview online 22 November 2013; published online 19 December 2013
Abbreviations: AJCC, American Joint Committee on Cancer; DFS, disease-free survival; MSM, melanoma-
specific mortality
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